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Summary
The 35 kDa thioesterase (TE) domain excised from the
megadalton tyrocidine synthetase (Tyc Syn) retains
autonomous capacity to macrocyclize peptidyl thio-
esters to D-Phe1-L-Leu10-macrolactams. Since a num-
ber of nonribosomal peptides undergo O-glycosylation
events during tailoring to gain biological activity, the
Tyc Syn TE domain was evaluated for cyclization ca-
pacity with glycosylated peptidyl-S-NAC substrates.
First, Tyr7 was replaced with Tyr(-D-Gal) and Tyr
(-D-Glc) as well as with Ser-containing -linked D-Gal,
D-Glc, D-GlcNAc, and D-GlcNH2, and these new analogs
were shown to be cyclized with comparable kcat/Km ca-
talytic efficiency. Similarly, Gal- or tetra-O-acetyl-Gal-Ser
could also be substituted at residues 5, 6, and 8 in the
linear decapeptidyl-S-NAC sequences and cyclized
without substantial loss in catalytic efficiency by Tyc
Syn TE. The cyclic glycopeptides retained antibiotic ac-
tivity as membrane perturbants in MIC assays, opening
the possibility for library construction of cyclic glyco-
peptides by enzymatic macrocyclization.
Introduction
A variety of peptidyl, lipopeptidyl, and hybrid polyketi-
dyl-peptidyl natural products are generated as macro-
cyclic lactams and lactones in which the conforma-
tional constraints introduced by cyclizations restrict
architecture to biologically active conformations [1, 2].
These classes of natural products are elongated from
simple amino acid and acyl CoA monomer units by mul-
timodular enzymatic assembly lines as a series of acyl-S-
enzyme covalent intermediates [1, 2]. Full-length acyl-S-
enzymes undergo self-catalyzed chain termination by
30–40 kDa thioesterase domains, situated at the C-termi-
nal end of the assembly lines [1, 2]. A variety of TE
domains, when excised and expressed as a single do-
main, retain autonomous activity to act as regioselec-
tive and stereoselective macrocyclization catalysts [3–
6], both on soluble thioester substrates and for sub-
strates tethered on solid support beads [3, 7].*Correspondence: wong@scripps.edu; christopher_walsh@hms.
harvard.edu
3 These authors contributed equally to this work.The nascent cyclic products released by TE domain
catalysis often undergo a series of subsequent tailoring
reactions, most commonly oxidations and glycosyl-
ations, carried out by dedicated tailoring enzymes en-
coded with the assembly line genes in biosynthetic
gene clusters [1, 8]. The glycosylations may be required
for gain of biological activity, as in the erythromycin
family [9], or as scaffolds for further enzymatic decora-
tion to create the pharmacophores [10]. We have fo-
cused on characterization of such glycosyltransferases
as an approach to diversify natural product structure
and activity [11–15].
In parallel, we have begun to explore chemical incor-
poration of glycosylated amino acids into linear peptide
precursors to act as substrates for the macrocyclizing
thioesterases. As an initial test, we turned to the tyro-
cidine synthetase TE domain (Tyc Syn TE), which we
have previously determined to be an efficient head-to-
tail cyclization catalyst with decapeptidyl thioesters,
generating the natural cyclic decapeptide tyrocidine
and a variety of backbone analogs [3, 16–19]. In partic-
ular, we have previously shown that Tyc Syn TE will tol-
erate replacement of residues 5–8 of peptidyl thioes-
ters. Therefore, we started with Tyr7 and replaced it with
protected glycosyl-β-Tyr and glycosyl-β-Ser residues
via solid-phase synthesis of monoglycosyl decapepti-
dyl thioesters. We also substituted residues 5–8 with
galactosyl-β-Ser to evaluate the permissiveness of Tyc
Syn TE to macrocyclize the regioisomeric monoglyco-
syl peptidyl thioesters. All cyclic products were tested
for minimal inhibitory concentrations as antibiotics and
for minimal hemolysis concentrations.
Results
Synthesis of Glycopeptide Thioesters
The decapeptidyl thioesters were synthesized essen-
tially as previously reported [3], by solid-phase peptide
synthesis with Fmoc-protected amino acids, including
Tyr(Ac4-β-D-Gal), Tyr(Ac4-β-D-Glc), Ser(Ac4-β-D-Gal),
Ser(Ac4-β-D-Glc), Ser(Ac3-β-D-GlcNAc), and Ser(Ac3-β-
D-GlcNBoc) in place of Tyr7, as depicted in Figure 1.
The hydroxyl groups of the sugar were protected with
acetyl groups, which were removed before conversion
to the N-acetylcysteamine (NAC) thioester, and enzy-
matic cyclization assays were performed as noted.
Analogously Fmoc-Ser(Ac4-β-D-Gal) was used in place
of Asn5, Gln6, and Val8 during solid-phase synthesis of
the linear peptides (Figure 1).
Substrate Behavior of Glycosylated
Peptidyl-S-NACs
The excised TE domain from tyrocidine synthetase will
accept soluble decapeptidyl-S-NAC thioesters in place
of the decapeptidyl-S-pantotheinyl-phospho-carrier pro-
tein domain that is the natural acyl-S-enzyme upstream
substrate in tyrocidine synthetase [3]. The head-to-tail
cyclization is shown in Figure 2 for both the wild-type
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1636Figure 1. Synthesis of Glycosylated Amino
Acids and Incorporation into Linear Peptidyl-
S-NAC Thioesters via Solid-Phase Peptide
Synthesisdecapeptidyl-S-NAC and the monoglucosyl-serine ver- 1
Ssions at residue 7 (Figure 2).
Table 1 shows, as expected from earlier studies [17, in KM and a 2-fold drop in kcat, yielding a 20-fold
Figure 2. Tyc Syn TE-Catalyzed Head-to-Tail
Cyclization to Produce Tyrocidine and Gly-
cosyl-Tyrocidine Variants, with Ser7(β-D-Glc)
Shown as an Example9], that Tyc Syn TE tolerates replacement of Tyr7 by
er, albeit with cyclization kinetics of a 10-fold increase
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1637Table 1. Kinetic Parameters of Tyc Syn TE-Catalyzed Cyclization of Peptide Thioesters Substituted with Different Glycosyl-Tyr and -Ser at
Position 7
kcat/Km Cyclization to Hydrolysis Cyclization to Hydrolysis
kcat (min−1)a Km (M)a (min−1 M−1) Ratio at 5 Mb Ratio at 50 Mb
Tyrocidine 110 1.4 79 17.2 ± 0.4 12.3 ± 0.3
Tyr7(β-D-Gal) 59 8.5 6.9 10.1 ± 0.4 8.6 ± 0.1
Tyr7(β-D-Glc) 82 8.3 9.9 10.8 ± 0.2 8.2 ± 0.1
Ser7 69 15.0 4.6 6.7 ± 0.5 5.3 ± 0.5
Ser7(β-D-Gal) 55 12.2 4.5 6.2 ± 0.1 5.6 ± 0.1
Ser7(β-D-Glc) 55 15.4 3.6 10.8 ± 0.1 7.7 ± 0.1
Ser7(β-D-GlcNAc) 101 11.4 8.9 10.6 ± 0.2 6.1 ± 0.2
Ser7(β-D-GlcNH2) 140 4.3 32.6 11.1 ± 0.1 8.0 ± 0.1
a For the kcat and Km measurements, reactions were carried out with 5 nM TE, and substrate concentrations used were 0.5, 1, 2, 5, 10, 20,
and 40 M.
b For the cyclization to hydrolysis ratio measurement, reactions were carried out with 50 nM TE at two different substrate concentrations, 5
and 50 M. The cyclization to hydrolysis ratios were measured by LCMS after the reactions were complete in 1 hr.decrease in catalytic efficiency. Tyr7(β-D-Gal) and
Tyr7(β-D-Glc) are slightly poorer substrates than the
wild-type Tyr7 peptidyl-S-NAC by only about 8-fold in
KM and are almost equivalent in kcat, confirming toler-
ance by the TE to the addition of a hydrophilic sugar.
Substitution of Tyr7 by Ser or any of four glycosyl-serines,
including N-acetyl-glucosaminyl- and 2-amino-2-deoxy-
glucosyl-O-Ser7, could be done without substantial
penalty for subsequent head-to-tail macrocyclization
by the enzyme. This suggests a prospect of subse-
quent chemical and/or enzymatic acylation strategies
to make cyclic lipoglycopeptides by these approaches.
In terms of the cyclization to hydrolysis ratio mediated
by the TE domain, the Tyr7(β-D-Gal) and Tyr7(β-D-Glc)
substrates gave ratios of 8:1–10:1 under conditions in
which the Tyr7 wild-type decapeptidyl-S-NAC sequence
was cyclized at ratios of 12:1–17:1. These ratios provide
synthetically useful flux to regiospecific macrocycliza-
tion of the monoglycosylated peptides. Table 1 also
displays data for the corresponding TE domain-medi-
ated cyclization of Ser7(β-D-Gal)-, Ser7(β-D-Glc)-,
Ser7(β-D-GlcNAc)-, and Ser7(β-D-GlcNH2)-decapeptidyl
thioesters. All four glycosylated Ser7 peptides are
macrocyclized with 85%–90% of the flux to the macro-
lactam (Table 1).
To evaluate the tolerance of the Tyc Syn TE domain
for glycosylated residues at other sites, Ser(β-D-Gal)-
or Ser(Ac4-β-D-Gal)-peptidyl thioesters were synthe-
sized with the sugar substituent displayed at residue 5,
6, or 8 on the decapeptidyl thioester backbone, replac-
ing Asn5, Gln6, or Val8, respectively. In all cases, the
unglycosylated serine-containing peptides (Ser5, Ser6,
Ser8) were prepared and assayed with the TE domain
for comparison to the substrates containing glycosyl-
serine. At positions 5–7, the galactosyl and tetra-O-
acetyl-galactosyl substituents were accommodated
with remarkably little perturbation (Table 2), consistent
with the view [16] that this portion of the linear sub-
strate does not make significant contact with the en-
zyme active site. Cyclization to hydrolysis ratios ranged
from 7:1 to 13:1, indicating that 85%–95% of the flux is
directed by the enzyme to intramolecular capture by
the amine nucleophile of D-Phe1. At residue 8, while
the replacement of Val8 for Ser is well tolerated, the
galactosyl-O-serine substitution, with and without the
four acetyl groups, has a substantial effect on the pro-
duct-determining step. While k is not substantially al-cattered, now 50% of the flux in the Ser8(β-D-Gal) and 80%
of the flux in the Ser8(Ac4-β-D-Gal) is to hydrolysis, sug-
gesting that a cyclization conformer in the acyl-O-TE
active site is disfavored by the sugar substituent at resi-
due 8 (Table 2).
Biological Activity of Glycosylated
Tyrocidine Derivatives
The antibiotic activity of tyrocidine arises from its pene-
tration into bacterial membranes and subsequent pore
formation. The selectivity of bacterial membranes ver-
sus eukaryotic membranes is not particularly high, lim-
iting the systemic use of this class of cyclic peptide
antibiotics [20]. We evaluated the minimal inhibitory
concentration (MIC) against Bacillus subtilis and the
minimal hemolytic concentration (MHC) against human
erythrocytes as a typical eukaryotic cell membrane tox-
icity [21, 22]. As shown in Table 3, the MIC for the par-
ent tyrocidine was 1.5 M, while the MHC was 25 M,
yielding an MHC:MIC ratio of 16. The Ser5, Ser6, Ser7,
and Ser8 variants had MHC:MIC ratios of 4–8, as did
the Tyr7(β-D-Glc) and Tyr7(β-D-Gal) cyclic macrolac-
tams. The presence of galactosyl, 2-aminoglucosyl,
and GlcNAc on Ser7 or galactosyl and tetra-O-acetyl
galactosyl residues on Ser5–7 had only minimal effects
on MIC and MHC values. However, the galactosylation
at Ser8 in both acetylated and nonprotected form raised
the MIC 15- and 2-fold, respectively, while the MHC val-
ues increased 8- and 4-fold, respectively. Thus, glyco-
syl substitution at residue 8 appears to impair the mem-
brane activity of the cyclic peptide (Table 3).
Discussion
The tyrocidine synthetase TE domain acts as the last
domain in a 28-domain, 3-protein, megadalton nonribo-
somal peptide synthetase assembly line [23]. As the
most downstream domain in the assembly line, the 30
kDa TE acts as the chain termination catalyst, causing
head-to-tail macrocyclization of the amino group of
D-Phe1 on the activated carbonyl of L-Leu10. The ex-
cised TE domain is soluble, well folded, and autono-
mously active as a regiospecific macrolactamization
catalyst. Prior work has indicated a broad tolerance of
the excised TE for replacement of the side chains of
the four residues, D-Phe , Asn , Gln , and Tyr , with re-4 5 6 7
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1638Table 2. Kinetic Parameters of Tyc Syn TE-Catalyzed Cyclization of Peptide Thioesters Substituted with Ser, Ser(β-D-Gal), and Ser(Ac4-β-D-
Gal) at Positions 5–8
kcat/Km Cyclization to Hydrolysis Cyclization to Hydrolysis
kcat (min−1) Km (M) (min−1 M−1) Ratio at 5 M Ratio at 50 M
Ser5 46 0.8 58.5 7.3 ± 0.4 5.3 ± 0.1
Ser5(β-D-Gal) 68 2.0 34 13.0 ± 1.6 8.9 ± 0.1
Ser5(Ac4-β-D-Gal) 111 4.4 25.2 6.9 ± 0.6 4.7 ± 0.1
Ser6 42 0.5 84 13.6 ± 0.2 11.8 ± 0.7
Ser6(β-D-Gal) 22 2.5 8.8 8.1 ± 0.1 7.0 ± 0.1
Ser6(Ac4-β-D-Gal) 24 2.5 9.6 10.0 ± 0.3 7.7 ± 0.1
Ser7 69 15.0 4.6 6.7 ± 0.5 5.3 ± 0.5
Ser7(β-D-Gal) 55 12.2 4.5 6.2 ± 0.1 5.6 ± 0.1
Ser7(Ac4-β-D-Gal) 40 13.8 2.9 3.9 ± 0.4 7.7 ± 0.1
Ser8 112 6.2 18.1 9.8 ± 0.1 5.8 ± 0.3
Ser8(β-D-Gal) 39 9.6 4.1 1.1 ± 0.2 1.3 ± 0.1
Ser8(Ac4-β-D-Gal) 94 14.3 6.6 0.21 ± 0.02 0.27 ± 0.01
Assay conditions were the same as in Table 1.lresidues 5–8. Only at residue 8 did the substitution in-
t
p
aTable 3. MIC, MHC, and Therapeutic Index of Glycopeptides
Made p
d
Therapeutic
cMIC (M) MHC (M) Index (MHC/MIC)
i
Tyrocidine 1.5 25 16
bSer5 3 12.5 4
rSer5(β-D-Gal) 6 50 8
sSer5(Ac4-β-D-Gal) 6 25 4
Ser6 1.5 12.5 8 a
Ser6(β-D-Gal) 3 50 16 s
Ser6(Ac4-β-D-Gal) 6 25 4 c
Ser7 1.5 12.5 8 sSer7(β-D-Gal) 3 50 16
pSer7(Ac4-β-D-Gal) 3 25 8
mSer7(β-D-Glc) 6 50 8
Ser7(β-D-GlcNAc) 6 50 8
Ser7(β-D-GlcNH2) 6 50 8 STyr7(β-D-Gal) 6 50 8
Tyr7(β-D-Glc) 6 50 8
Ser8 6 25 4 A
Ser8(β-D-Gal) 100 200 2 u
Ser8(Ac4-β-D-Gal) 12 100 8 atention of regiospecific macrocyclization capacity [3, 7, t
m16–19].
Since many nonribosomal peptides undergo post-
massembly line tailoring by dedicated glycosyltransfer-
ases [1, 8, 24] to create glycopeptides in which solubil- p
tity and/or biological activity is altered by the tailoring
process, we have begun to explore in this work whether m
cone could provide glycosylated substrates to this TE
domain and still see effective head-to-tail cyclization. t
dTo that end, we have replaced each of residues 5–8
with a serine side chain and observed maintenance of s
pgood ratios of enzymatic cyclization to hydrolysis of the
serine-containing peptidyl thioesters. Our initial focus i
on Tyr7 shows that incorporation of Tyr(β-D-Gal) or Tyr
(β-D-Glc) during solid-phase synthesis of the decapep- n
ctidyl-S-NACs caused no problem for enzyme-directed
flux of head-to-tail cyclization. Furthermore, four dif- g
nferent β-glycosyl-Ser7 substitutions for Tyr7 were also
not deleterious to TE-mediated flux to macrolactamiza- c
Ttion. Subsequently, we substituted Ser(β-D-Gal) in de-
protected or tetra-O-acetyl-protected forms at each of lerfere noticeably with the D-Phe1-L-Leu10 enzymatic
acrocyclization.
We do not expect a priori for glycosylation of the
embrane-seeking cyclic tyrocidine peptides to im-
rove either antibiotic efficacy or necessarily reduce
he liability of nonspecific pore formation in eukaryotic
embranes (measured as hemolysis of human red
ells). In fact, most of the glycosylated tyrocidines re-
ained their antibiotic activity with equal or marginally
ecreased tendency to hemolysis. These initial data
uggest that one could create libraries of glycosylated
eptides to evaluate these and other biological activ-
ties.
Using the combination of chemoenzymatic steps
oted here, it should be feasible to make libraries of
yclic tyrocidine peptides with monosaccharides or oli-
osaccharides at multiple residues. However, there is
o reason to believe this approach is limited to the tyro-
idine synthetase TE. We and others have noted that
E domains excised from additional NRPS assembly
ines [4–6] retain stereo- and regiospecificity as cata-
ysts to make branched macrocycles, both macrolac-
ams and macrolactones. Therefore, libraries of glyco-
eptides on different peptide scaffolds should be
ccessible by use of glycosyl amino acids in solid-
hase synthesis followed by macrocyclization by TE
omains. This approach should be equally valid for
onverting lipopeptide antibiotics (e.g., daptomycin)
nto lipoglycopeptides. Further, converting the back-
ones of hybrid polyketide/nonribosomal peptides to
egiospecific glycosylated versions may also be pos-
ible, provided the macrocyclizing TE domains show
ppropriate tolerance to glycosylation away from the
ite of macrocyclization. It should also be possible to
hemically incorporate oligosaccharyl as well as mono-
accharyl chains before or after TE-mediated scaffold
eptide cyclizations, thereby providing a useful way to
ake glycopeptide immunogens.
ignificance
variety of nonribosomal peptide and polyketide nat-
ral products undergo regiospecific macrocyclization
s the chain release step from their enzymatic assem-
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1639bly lines. Many of these cyclic products then undergo
glycosylation by dedicated tailoring glycosyltransfer-
ases. Glycosylation increases aqueous solubility, can
protect the producer microorganism from the actions
of the antibiotic, and/or can be required for biological
activity. An alternative to nature’s use of tandem en-
zymatic steps of macrocyclization and glycosylation
is a chemoenzymatic approach of glycopeptide thio-
ester synthesis followed by enzymatic macrocycliza-
tion. The excised thioesterase domain of tyrocidine
synthetase was used as a prototype to validate that
Tyr7 could be replaced by glycosyl-O-Tyr and glyco-
syl-O-Ser residues via solid-phase synthesis, and the
modified peptidyl thioesters then undergo TE-medi-
ated D-Phe1-L-Leu10 head-to-tail macrocyclization.
Enzymatic macrolactamization proceeded with equal
efficiency (80%–95%) for both glycosylated and non-
glycosylated peptide thioesters. Three other resi-
dues, Asn5, Gln6, and Val8, could also be replaced
with galactosyl-O-Ser residues and could be cyclized
by the TE domain. Only the galactosyl-O-Ser8 sub-
strate showed lower flux to cyclization. The glycosy-
lated-O-tyrocidine peptides retained antimicrobial ac-
tivity but tended to be slightly less hemolytic. This
chemoenzymatic approach to glycopeptides should
be generalizable to TE domains from NRPS, PKS, and
hybrid NRPS/PKS assembly lines, with distinct regio-
and stereochemistry of macrolactamization and
macrolactonization to create libraries of neoglycosy-
lated natural products.
Experimental Procedures
General Procedures for Chemical Synthesis
All chemicals were purchased as reagent grade and were used
without further purification. Dichloromethane (CH2Cl2) was distilled
over calcium hydride, and tetrahydrofuran (THF) and diethyl ether
were distilled over sodium/benzophenone ketyl. Anhydrous DMF
was purchased from a commercial source. Reactions were moni-
tored with analytical thin-layer chromatography (TLC) on silica gel
60 F254 plates and visualized under UV (254 nm) and/or by staining
with acidic cerium ammonium molybdate. 1H NMR spectra were
recorded on a 500 MHz spectrometer. Fmoc-Ser-OAll and Fmoc-
Tyr-OAll were prepared according to the published procedure for
allyl ester protection of amino acids [25].
General Procedure for Glycosylation
of Amino Acid Allyl Esters
The Fmoc amino acid allyl ester (1 eq) and the peracetylated glyco-
syl donor (1 eq) were dissolved in dry CH2Cl2 under argon. The
solution was cooled to 0°C, and BF3·OEt2 (3 eq) was added drop-
wise. The reaction was monitored by TLC, and after the glycosyl
donor was nearly consumed (w2 hr, unless otherwise noted), addi-
tional glycosyl donor (0.7–1 eq) and BF3·OEt2 (0.7–1 eq) were
added. If the glycosyl donor was consumed again and amino acid
acceptor remained, additional glycosyl donor (1 eq) and BF3·OEt2
(1 eq) were added, and the reaction was stirred overnight. The re-
action was diluted with CH2Cl2, washed with 0.5 M aqueous
NaHSO4, and then washed with H2O. The organic phase was dried
over MgSO4, filtered, and concentrated. The residue was purified
by flash chromatography on a silica gel column; elution with a gra-
dient of ethyl acetate in hexanes (25%–50%) afforded the Fmoc
glycosyl amino acid allyl ester as a white foam.
General Procedure for Allyl Ester Removal
from Glycosyl Amino Acids
The Fmoc glycosyl amino acid (1 eq) and tetrakis(triphenylphos-
phine)palladium(0) (Pd(PPh ) , 0.01 eq) were dissolved in dry CH Cl3 4 2 2under argon. Morpholine (1.9 eq) was added dropwise. The reac-
tion was stirred for 20 min, at which point the reaction was com-
plete by TLC. The reaction was diluted with CH2Cl2, washed with
10% citric acid twice, and washed with brine once. The organic
layer was dried over MgSO4 and concentrated. The product was
determined to be pure by NMR and was either used as is or after
removal of the palladium with MP-TMT resin (Argonaut).
N-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl--D-
galactopyranosyl)-L-serine Allyl Ester (1a)
Compound 1a was prepared by reaction of Fmoc-Ser-OAll (0.8 g,
2.18 mmol, 1 eq) and β-D-galactose pentaacetate (2.55 g, 6.53
mmol, 3 eq) in dry CH2Cl2 under BF3·OEt2 promotion at 4°C by
adding the glycosyl donor in three separate 1 eq additions accord-
ing to the general procedure. The reaction was monitored by TLC
with 25% ethyl acetate/hexanes run three times, Rf = 0.08: (1.12 g,
74%); Rf = 0.3 (40% ethyl acetate/hexanes); 1H NMR (500 MHz,
CDCl3) δ 1.99, 2.01, 2.03, 2.15 (4s, 3H each, Ac), 3.85 (t, 1H, J = 6.5
Hz, H-5), 3.89 (dd, 1H, J = 3.5 and 11 Hz, H-β), 4.11 (d, 2H, J = 7.0
Hz, H-6, H-6#), 4.24 (t, 1H, J = 7.0 Hz, Fmoc CH), 4.29 (dd, 1H, J =
3.0 and 10.5 Hz, H-β#), 4.4–4.45 (m, 1H, Fmoc OCH2), 4.44 (d, 1H,
J = 8.0 Hz, H-1), 4.45–4.55 (m, 2H, H-α, Fmoc OCH2), 4.68 (d, 2H,
J = 5.5 Hz, allyl OCH2), 5.00 (dd, 1H, J = 3.5 and 10.5 Hz, H-3), 5.16
(dd, 1H, J = 8.0 and 10 Hz, H-2), 5.25 (dd, 1H, J = 1.0 and 10.5 Hz,
allyl CH=CH2), 5.34 (d, 1H, J = 17 Hz, allyl CH=CH2), 5.38 (d, 1H,
J = 3.0 Hz, H-4), 5.59 (d, 1H, J = 8.0 Hz, NH), 5.90 (m, 1H, allyl CH=
CH2), 7.3–7.8 (dd, dd, t, m, 8H, Fmoc Ar); MALDI-MS of C35H39NO14
(M, 698) m/z 721 ([M+Na]+); high-resolution MS (HRMS, ESI-TOF
high-acc) m/z calcd for C35H39NO14 ([M+Na]+) 720.2263, found
720.2259.
N-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl--D-
galactopyranosyl)-L-serine (1b)
Compound 1b was prepared by reaction of 1a (600 mg, 0.86 mmol)
with Pd(PPh3)4 (9.9 mg, 8.6 mol) and morpholine (143 l, 1.63
mmol) in CH2Cl2 (4 ml) according to the general procedure; spectral
data are in agreement with those reported [26, 27].
N-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl--D-
glucopyranosyl)-L-serine Allyl Ester (2a)
Compound 2a was prepared by reaction of Fmoc-Ser-OAll (414 mg,
1.13 mmol, 1 eq) and β-D-glucose pentaacetate (1.3 g, 3.33 mmol,
3 eq) in dry CH2Cl2 under BF3·OEt2 promotion at 4°C by adding the
glycosyl donor in three separate 1 eq additions according to the
general procedure. The reaction was monitored by TLC with 25%
ethyl acetate/hexanes run three times, Rf = 0.08: (346 mg, 44%);
Rf = 0.3 (40% ethyl acetate/hexanes); 1H NMR (500 MHz, CDCl3) δ
2.00, 2.01, 2.03, 2.07 (4s, 3H each, Ac), 3.65 (m, 1H, H-5), 3.86 (dd,
1H, J = 3 and 10.5, H-β), 4.10 (dd, 1H, J = 12 Hz), 4.23 (m, 2H, H-6#,
Fmoc CH), 4.29 (dd, 1H, J = 2.0 and 10.5 Hz, H-β#), 4.42 (dd, 1H, J =
7.0 and 10.5, Fmoc OCH2), 4.46–4.50 (m, 3H, Fmoc OCH2, H-1 (J =
7.5 Hz), H-α), 4.66 (d, 2H, J = 4.0 Hz, allyl OCH2), 4.95 (dd, 1H, J = 8.5
and 9.0 Hz, H-2), 5.06 (t, 1H, J = 9.5 Hz, H-4), 5.19 (t, 1H, J = 10.5 Hz,
H-3), 5.24 (d, 1H, J = 10.5 Hz, allyl CH=CH2), 5.32 (d, 1H, J = 17.5 Hz,
allyl CH=CH2), 5.62 (d, 1H J = 13.0 Hz), 5.89 (m, 1H, allyl CH), 7.3–7.8
(t, t, d, d, 8H, Fmoc Ar); MALDI-MS of C35H39NO14 (M, 698) m/z 721
([M+Na]+); HRMS (ESI-TOF high-acc) calcd for C35H39NO14 ([M+H]+)
698.2443, found 698.2438.
N-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl--D-
glucopyranosyl)-L-serine (2b)
Compound 2b was prepared by reaction of 2a (100 mg, 0.14 mmol)
with Pd(PPh3)4 (1.66 mg, 1.4 mol) and morpholine (24 l, 0.27
mmol) in CH2Cl2 (650 l) according to the general procedure;
spectral data are in agreement with those reported [26, 27].
N-(9-Fluorenylmethoxycarbonyl)-3-O-(2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamino)-3,4,6-tri-O-acetyl--D-
glucopyranosyl)-L-serine Allyl Ester (3)
Compound 3 was prepared by reaction of Fmoc-Ser-OAll (1.0 g,
2.72 mmol, 1 eq) and 1,3,4,6-tetra-O-acetyl-2-deoxy-2-(2#,2#,2#-
trichloroethoxycarbonylamino)-D-glucopyranoside (2.42 g, 4.62 mmol,
1.7 eq) in dry CH Cl under BF ·OEt promotion at room temper-2 2 3 2
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(stirred with 1 eq glycosyl donor at room temperature for 12 hr be-
fore addition of the remaining 0.7 eq. The reaction was monitored
by TLC with 25% ethyl acetate/hexanes run four times, Rf = 0.2: N
(1.8 g, 88%); Rf = 0.2 (40% ethyl acetate/hexanes); spectral data g
are in agreement with those reported [28]. C
m
0N-(9-Fluorenylmethoxycarbonyl)-3-O-(2-acetamido-3,4,6-tri-O-
bacetyl-2-deoxy--D-glucopyranosyl)-L-serine Allyl Ester (3a)
cGlycosyl amino acid 3 (150 mg, 0.18 mmol) and activated Zn dust
m(180 mg, 2.75 mmol) were dissolved in glacial acetic acid (2 ml) and
0stirred vigorously at room temperature for 4 hr. The reaction was
(filtered through Celite and dried under vacuum. Pyridine (2.25 ml)
(and acetic anhydride (1.13 ml) were added to this crude intermedi-
(ate. The reaction was stirred overnight at room temperature and
4then concentrated. The residue was dissolved in ethyl acetate (20
Oml) and then washed with 0.1 N HCl twice, saturated NaHCO3, and
Jbrine. The organic layer was dried over Na2SO4 and concentrated.
(The residue was purified by chromatography on a silica gel column;
5elution with a gradient of ethyl acetate in hexanes (60%–90%) af-
Jforded glycoside 3a as a white solid (108 mg, 86%); spectral data
Care in agreement with those reported [28].
m
N-(9-Fluorenylmethoxycarbonyl)-3-O-(2-acetamido-3,4,6-tri-O-
Nacetyl-2-deoxy--D-glucopyranosyl)-L-serine (3b)
gCompound 3b was prepared by reaction of 3a (63 mg, 0.09 mmol)
Cwith Pd(PPh3)4 (1.05 mg, 0.9 mol) and morpholine (15 l, 0.17
wmmol) in CH2Cl2 (500 l) according to the general procedure, ex-
mcept the workup was done with only one wash with 10% citric acid;
sspectral data are in agreement with those reported [28].
NN-(9-Fluorenylmethoxycarbonyl)-3-O-(3,4,6-tri-O-acetyl-2-tert-
gbutoxycarbonylamino-2-deoxy--D-glucopyranosyl)-L-serine
CAllyl Ester (4a)
mGlycosyl amino acid 3 (1 g, 1.2 mmol) and activated Zn dust (1.3 g,
m20 mmol) were dissolved in glacial acetic acid (10 ml) and stirred
avigorously at room temperature for 5 hr. The reaction was filtered
ithrough Celite and dried under vacuum. To this crude intermediate,
iunder argon, was added di-tert-butyl-dicarbonate (369 mg, 1.69
(mmol) and dry 1,4-dioxane (10 ml). Then, triethylamine (505 l, 3.62
Mmmol) was added dropwise. The reaction was stirred overnight at
aroom temperature and then concentrated. The residue was dis-
Hsolved in ethyl acetate (35 ml) and then washed with saturated
7NaHCO3 and then H2O. The organic layer was dried over Na2SO4
4and concentrated. The residue was purified by chromatography on
1a silica gel column; elution with a gradient of ethyl acetate in hex-
(anes (40%–60%) afforded glycoside 4a as a white solid (659 mg,
872%); Rf = 0.4 (50% ethyl acetate/hexanes); 1H NMR (500 MHz,
FCDCl3)· δ 1.41 (s, 9H, t-Bu), 2.02, 2.04, 2.06 (3s, 3H each, Ac), 3.50
H(m, 1H, H-2), 3.6–3.7 (m, 1H, H-5), 3.90 (dd, 1H, J = 2.5 and 10.5, H-β),
74.10 (dd, 1H, J = 2.0 and 12.5, H-6), 4.2–4.3 (m, 3H, H-6#, H-β#,
Fmoc CH), 4.33 (dd, 1H, J = 7.5 and 10.5, Fmoc OCH2), 4.48 (dd,
1H, J = 7.0 and 10.5, Fmoc OCH2), 4.56 (m, 1H, H-α), 4.6–4.7 (m, N
2H, allyl OCH2), 4.74 (br d, 1H, H-1), 5.02 (dd, 1H, J = 9.5 and 10, g
H-4), 5.2–5.4 (m, 3H, H-3, allyl CH=CH2), 5.87 (m, 2H, NH, allyl CH= C
CH2), 7.3–7.8 (m, t, t, d, 8H, Fmoc Ar); MALDI-MS of C38H46N2O14 w
(M, 755) m/z 778 ([M+Na]+); HRMS (ESI-TOF high-acc) m/z calcd m
for C38H46N2O14 ([M+Na]+) 777.2847, found 777.2845. s
SN-(9-Fluorenylmethoxycarbonyl)-3-O-(3,4,6-tri-O-acetyl-2-tert-
butoxycarbonylamino-2-deoxy--D-glucopyranosyl)- L
tL-serine (4b)
Compound 4b was prepared by reaction of 4a (68.3 mg, 0.09 mmol) w
awith Pd(PPh3)4 (1.05 mg, 0.9 mol) and morpholine (15 l, 0.17
mmol) in CH2Cl2 (500 l) according to the general procedure; Rf = a
t0.4 (10% methanol/CH2Cl2); 1H NMR (500 MHz, CDCl3)·δ 1.40 (s,
9H, t-Bu), 2.01, 2.03, 2.06 (3s, 3H each, Ac), 3.55 (m, 1H, H-2), 3.65 t
t(m, 1H, H-5), 3.96 (dd, 1H, J = 7.0 Hz), 4.1–4.2 (m, 1H, H-6), 4.2–4.3
(m, 3H, H-6#, H-β, Fmoc CH), 4.34 (dd, 1H, J = 7.5 and 10.5 Hz, c
Fmoc OCH2), 4.45 (dd, 1H, J = 7.0 and 8.0 Hz, Fmoc OCH2), 4.56
(m, 1H, H-α), 4.69 (br d, 1H, H-1), 5.02 (dd, 1H, J = 9.0 and 10.0 Hz, w
tH-4), 5.24 (m, 1H, H-3), 6.00 (d, 1H, J = 8.0 Hz, NH), 7.3–7.8 (m, t,
dd, d, 8H, Fmoc Ar); MALDI-MS of C H N O (M, 715) m/z 738 r35 42 2 14[M+Na]+); HRMS (ESI-TOF high-acc) m/z calcd for C35H42N2O14
[M+Na]+) 737.2528, found 737.2530.
-(9-Fluorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl--D-
alactopyranosyl)-L-tyrosine Allyl Ester (5a)
ompound 5a was prepared by reaction of Fmoc-Tyr-OAll (113.4
g, 0.26 mmol, 1 eq) and β-D-galactose pentaacetate (300.5 mg,
.77 mmol, 3 eq) in dry CH2Cl2 under BF3·OEt2 promotion at 4°C
y adding the glycosyl donor in three separate 1 eq additions ac-
ording to the general procedure (138 mg, 70%). The reaction was
onitored by TLC with 40% ethyl acetate/hexanes run twice, Rf =
.3: (138 mg, 70%); Rf = 0.16 (40% ethyl acetate/hexanes); 1H NMR
500 MHz, CDCl3) δ 2.02, 2.03, 2.04, 2.16 (4s, 3H each, Ac), 3.0–3.2
m, 2H, H-β, and -β#), 3.91 (t, 1H, J = 6.5 Hz, Fmoc CH), 4.05–4.2
m, 3H, Fmoc OCH2 and H-5), 4.28 (dd, 1H, J = 7.0 and 10.5 Hz, H-6),
.43 (dd, 1H, J = 7.0 and 10.5 Hz, H-6#), 4.62 (d, 2H, J = 5.5 Hz, allyl
CH2), 4.67 (m, 1H, H-α), 4.91 (d, 1H, J = 8.0 Hz, H-1), 5.08 (dd, 1H,
= 3.0 and 4.0 Hz, H-3), 5.25 (d, 1H, J = 10.5, allyl CH=CH2), 5.30
d, 1H, J = 17.5, allyl CH=CH2), 5.35–5.5 (m, 3H, NH, H-2, H-4), 5.8–
.95 (m, 1H, CH=CH2), 6.90 (d, 2H, J = 8.5 Hz, Tyr Ar), 7.04 (d, 2H,
= 8.5 Hz, Tyr Ar), 7.2–7.8 (m, t, dd, d, 8H, Fmoc Ar); MALDI-MS of
41H43NO14 (M, 774) m/z 797 ([M+Na]+); HRMS (ESI-TOF high-acc)
/z calcd for C41H43NO14 ([M+H]+) 774.2756, found 774.2750.
-(9-Fluorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl--D-
alactopyranosyl)-L-tyrosine (5b)
ompound 5b was prepared by reaction of 5a (70 mg, 0.09 mmol)
ith Pd(PPh3)4 (1.05 mg, 0.9 mol) and morpholine (15 l, 0.17
mol) in CH2Cl2 (500 l) according to the general procedure;
pectral data are in agreement with those reported [26].
-(9-Fluorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl--D-
lucopyranosyl)-L-tyrosine Allyl Ester (6a)
ompound 6a was prepared by reaction of Fmoc-Tyr-OAll (414.3
g, 1.13 mmol, 1 eq) and β-D-glucose pentaacetate (1.3 g, 3.33
mol, 3 eq) in dry CH2Cl2 under BF3·OEt2 promotion at 4°C by
dding the glycosyl donor in three separate 1 eq additions accord-
ng to the general procedure (346 mg, 44%). The reaction was mon-
tored by TLC with 40% ethyl acetate/hexanes run twice, Rf = 0.3:
346 mg, 44%); Rf = 0.16 (40% ethyl acetate/hexanes); 1H NMR (500
Hz, CDCl3) δ 2.02–2.04 (4s, 3H each, Ac), 3.0–3.2 (m, 2H, H-β,
nd -β#), 3.71 (m, 1H, H-5), 4.09 (m, 1H, H-6#), 4.17 (t, 1H, J = 7.0
z, Fmoc CH), 4.26 (m, 2H, H-6 and Fmoc OCH2), 4.44 (dd, 1H, J =
.0 and 10.5 Hz, Fmoc OCH2), 4.62 (d, 2H, J = 5.5 Hz, allyl OCH2),
.68 (q, 1H, J = 6.0 Hz, H-α), 4.94 (d, 1H, J = 7.0 Hz, H-1), 5.14 (t,
H, J = 9 Hz, H-4), 5.2–5.35 (m, 4H, H-2, H-3, Fmoc CH=CH2), 4.1
d, 1H, J = 7.5 Hz, NH), 5.87 (m, 1H, allyl CH=CH2), 6.89 (d, 2H, J =
Hz, Tyr Ar), 7.05 (d, 2H, J = 8 Hz, Tyr Ar), 7.2–7.8 (m, t, dd, d, 8H,
moc Ar); MALDI-MS of C41H43NO14 (M, 774) m/z 797 ([M+Na]+);
RMS (ESI-TOF high-acc) m/z calcd for C41H43NO14 ([M+H]+)
74.2756, found 774.2742.
-(9-Fluorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl--D-
lucopyranosyl)-L-tyrosine (6b)
ompound 6b was prepared by reaction of 6a (100 mg, 0.13 mmol)
ith Pd(PPh3)4 (1.5 mg, 1.3 mol) and morpholine (21.4 l, 0.25
mol) in CH2Cl2 (600 L) according to the general procedure;
pectral data are in agreement with those reported [26].
ynthesis of Linear Peptide N-acetylcysteamine Thioesters
inear peptides were synthesized by hand or on a Symphony pep-
ide synthesizer by using leucine-derivatized 2-chlorotrityl resin
ith five equivalents of 0.2 M Fmoc-protected amino acids in DMF
nd diisopropylcarbodiimide/hydroxybenzotriazole (DIPCDI/HOBt)
ctivation, except that the last amino acid, D-Phe1, was Boc pro-
ected. The peptides were cleaved from the solid support with 1:1:3
rifluoroethanol:acetic acid:CH2Cl2, and the protected linear pep-
ides were obtained by azeotrope with hexanes to remove the
leavage reagents.
To remove the acetyl protecting groups on sugars, the peptides
ere treated with 0.2 M sodium methoxide in methanol for 15 min,
hen the reaction was quenched with DOWEX 50WX8-200 acidic
esin, filtered, and concentrated. Alternatively, the acetyl protecting
A Chemoenzymatic Approach to Cyclic Glycopeptides
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for 5 hr before cleavage of the peptide from the solid support.
To make the N-acetylcysteamine thioester, the peptides (25
mol) were mixed with NAC (53 l, 500 mol), dicyclohexylcarbodi-
imide (16 mg, 75 mol), HOBt (12 mg, 75 mol), and diisopropyleth-
ylamine (17 l, 100 mol) in THF (0.5 ml). The reaction was agitated
at room temperature for 3 hr to overnight. After removal of the THF,
the peptide thioesters were deprotected with 95:5:5 TFA:water:tri-
isopropylsilane (2 ml) or 16:3:1 TFA:CH2Cl2:NAC at ambient temper-
ature for 4 hr. Then the peptide thioesters were precipitated with
cold ether (40 mL), and the precipitates were collected by centrifu-
gation. The precipitates were then dissolved in 50% acetonitrile/
water and purified by reverse-phase (C18) HPLC with a gradient of
20%–100% acetonitrile/0.1% TFA over 60 min. The peptidyl-S-NACs
were characterized by MALDI: Tyc-S-NAC m/z 1390 ([M+H]+), calcd
1388.7; Ser5-S-NAC m/z 1363 ([M+H]+), calcd 1361.7; Ser5(Ac4-β-D-
Gal)-S-NAC m/z 1691(M+), calcd 1691.8; Ser5(β-D-Gal)-S-NAC m/z
1524 (M+), calcd 1523.7; Ser6-S-NAC m/z 1348 (M+), calcd 1347.7;
Ser6(Ac4-β-D-Gal)-S-NAC m/z 1677 (M+), calcd 1677.8; Ser6(β-D-Gal)-
S-NAC m/z 1510 (M+), calcd 1509.7; Ser7-S-NAC m/z 1313 (M+),
calcd 1312.7; Ser7(Ac4-β-D-Gal)-S-NAC m/z 1643 (M+), calcd 1642.8;
Ser7(β-D-Gal)-S-NAC m/z 1476 ([M+H]+), calcd 1474.7; Ser7(β-D-Glc)-
S-NAC m/z 1476 ([M+H]+), calcd 1474.7; Ser7(β-D-GlcNAc)-S-NAC m/z
1517 ([M+H]+), calcd 1515.7; Ser7(β-D-GlcNH2)-S-NAC m/z 1475
([M+H]+), calcd 1473.7; Tyr7(β-D-Gal)-S-NAC m/z 1552 ([M+H]+), calcd
1550.8; Tyr7(β-D-Glc)-S-NAC m/z 1552 ([M+H]+), calcd 1550.8; Ser8-
S-NAC m/z 1377 (M+), calcd 1376.7; Ser8(Ac4-β-D-Gal)-S-NAC m/z
1707 (M+), calcd 1706.8; Ser8(β-D-Gal)-S-NAC m/z 1539 (M+),
calcd 1538.7.
Determination of kcat, Km, and Cyclization to Hydrolysis Ratio
The lyophilized products were dissolved in water for TE-catalyzed
cyclization reactions. The reactions were carried out in 25 mM
MOPS buffer (pH 7) with 0.1% Brij58. The substrate concentrations
used were 0.5, 1, 2, 5, 10, 20, and 40 M, and the enzyme concen-
tration used was 5 nM. Otherwise, the procedure was the same as
reported earlier [3]. To get kcat, Km values, the initial reaction rates
obtained were fit to the Michaelis-Menten equation, with R values
greater than 0.96.
To determine the cyclization to hydrolysis ratio, reactions were
carried out in triplicate in 25 mM MOPS buffer (pH 7) with 0.1%
Brij58. The substrate concentrations used were 5 M and 50 M,
and the TE concentration was 50 nM. After 1 hr, the reaction was
complete, and the cyclization to hydrolysis ratio was determined
by LCMS by using the area of absorption at 220 nm.
Preparation of Cyclized Glycopeptides
100 M peptidyl-S-NAC thioesters were incubated for 3 hr with 1
M Tyc TE in 25 mM MOPS (pH 7) and 0.1% Brij58. The cyclic
peptides were purified by preparative HPLC. Lyophilized cyclic
peptides were dissolved in methanol. The purities were checked
by analytical RP-HPLC (20%–100% acetonitrile/0.1% TFA), and the
concentrations were determined by comparing the area of absorp-
tion at 220 nm with that of a known concentration of tyrocidine
linear peptide thioester. The cyclic peptides were characterized by
LCMS or MALDI: Tyc m/z 1271 ([M+H]+), calcd 1269.7; Ser5 m/z
1243 (M+), calcd 1242.6; Ser5(Ac4-β-D-Gal) m/z 1573 (M+), calcd
1572.7; Ser5(β-D-Gal) m/z 1405 (M+), calcd 1404.7; Ser6 m/z 1229
(M+), calcd 1228.6; Ser6(Ac4-β-D-Gal) m/z 1559 (M+), calcd 1558.7;
Ser6(β-D-Gal) m/z 1391 (M+), calcd 1390.7; Ser7 m/z 1194 (M+),
calcd 1193.6; Ser7(Ac4-β-D-Gal) m/z 1524 (M+), calcd 1523.7;
Ser7(β-D-Gal) m/z 1356 (M+), calcd 1355.7; Ser7(β-D-Glc) m/z 1356
(M+), calcd 1355.7; Ser7(β-D-GlcNAc) m/z 1397 (M+), calcd 1396.7;
Ser7(β-D-GlcNH2) m/z 1355 (M+), calcd 1354.7; Tyr7(β-D-Gal) m/z
1432 (M+), calcd 1431.7; Tyr7(β-D-Glc) m/z 1432 (M+), calcd 1431.7;
Ser8 m/z 1258 (M+), calcd 1257.6; Ser8(Ac4-β-D-Gal) m/z 1588 (M+),
calcd 1587.7; Ser8(β-D-Gal) m/z 1420 (M+), calcd 1419.7.
MIC and MHC Determination for Variant Cyclic Peptides
In a 96-well plate, cylic peptides were serially diluted in methanol
and dried in a speedvac. For minimal inhibitory concentration (MIC)
testing, an overnight B. subtilis PY79 culture was diluted (1/10,000)
with LB media, and 80 µl of the diluted culture was added to eachwell. After overnight incubation at 30°C, the concentrations re-
quired for complete inhibition of bacterial cell growth were deter-
mined by visual inspection. Minimal hemolytic concentration (MHC)
values were determined by the addition of 80 µl of human red blood
cells (Research Blood Components) diluted (1/100) with PBS buffer
(pH 7.4) to dried peptides. RBCs were incubated at room temper-
ature overnight, and concentrations required for complete lysis
were determined visually.
Acknowledgments
This work is supported in part by National Institutes of Health (NIH)
grant GM20011 (C.T.W.), NIH grant GM44154 (C.-H.W.), the Jane
Coffin Childs Memorial Fund for Medical Research (H.L.), and the
National Science Foundation Predoctoral Fellowship (D.A.T.).
Received: July 26, 2004
Revised: September 7, 2004
Accepted: September 24, 2004
Published: December 17, 2004
References
1. Walsh, C.T. (2004). Polyketide and nonribosomal peptide antibi-
otics: modularity and versatility. Science 303, 1805–1810.
2. Kohli, R.M., and Walsh, C.T. (2003). Enzymology of acyl chain
macrocyclization in natural product biosynthesis. Chem. Com-
mun. 7, 297–307.
3. Trauger, J.W., Kohli, R.M., Mootz, H.D., Marahiel, M.A., and
Walsh, C.T. (2000). Peptide cyclization catalysed by the thioes-
terase domain of tyrocidine synthetase. Nature 407, 215–218.
4. Tseng, C.C., Bruner, S.D., Kohli, R.M., Marahiel, M.A., Walsh,
C.T., and Sieber, S.A. (2002). Characterization of the surfactin
synthetase C-terminal thioesterase domain as a cyclic depsi-
peptide synthase. Biochemistry 41, 13350–13359.
5. Sieber, S.A., Tao, J., Walsh, C.T., and Marahiel, M.A. (2004).
Peptidyl thiophenols as substrates for nonribosomal peptide
cyclases. Angew. Chem. Int. Ed. Engl. 43, 493–498.
6. Grunewald, J., Sieber, S.A., and Marahiel, M. (2004). Chemo-
and regioselective peptide cyclization triggered by the N-termi-
nal fatty acid chain length: the recombinant cyclase of the
calcium-dependent antibiotic from Streptomyces coelicolor.
Biochemistry 43, 2915–2925.
7. Kohli, R.M., Walsh, C.T., and Burkart, M.D. (2002). Biomimetic
synthesis and optimization of cyclic peptide antibiotics. Nature
418, 658–661.
8. Walsh, C.T. (2002). Combinatorial biosynthesis of antibiotics:
challenges and opportunities. ChemBioChem 3, 124–134.
9. Staunton, J., and Wilkinson, B. (1997). Biosynthesis of Erythro-
mycin and Rapamycin. Chem. Rev. 97, 2611–2630.
10. Lewis, R.J., Singh, O.M., Smith, C.V., Skarzynski, T., Maxwell,
A., Wonacott, A.J., and Wigley, D.B. (1996). The nature of inhi-
bition of DNA gyrase by the coumarins and the cyclothialidines
revealed by X-ray crystallography. EMBO J. 15, 1412–1420.
11. Hosey, H.C., Peczuh, M.W., Chen, Z., Eggert, U.S., Dong, S.D.,
Pelczer, I., Kahne, D., and Walsh, C.T. (2001). Tandem action
of glycosyltransferases in the maturation of vancomycin and
teicoplanin aglycones: novel glycopeptides. Biochemistry 40,
4745–4755.
12. Losey, H.C., Jiang, J., Biggins, J.B., Oberthur, M., Ye, X.Y.,
Dong, S.D., Kahne, D., Thorson, J.S., and Walsh, C.T. (2002).
Incorporation of glucose analogs by GtfE and GtfD from the
vancomycin biosynthetic pathway to generate variant glyco-
peptides. Chem. Biol. 9, 1305–1314.
13. Meyers, C.L.F., Oberthur, M., Anderson, J.W., Kahne, D., and
Walsh, C.T. (2003). Initial characterization of novobiocic acid
noviosyl transferase activity of NovM in biosynthesis of the an-
tibiotic novobiocin. Biochemistry 42, 4179–4189.
14. Lu, W., Leimkuhler, C., Oberthür, M., Kahne, D., and Walsh, C.T.
(2004). AknK is an L-2-deoxyfucosyltransferase in the biosyn-
thesis of the anthracycline aclacinomycin A. Biochemistry 43,
4548–4558.
Chemistry & Biology
164215. Lu, W., Oberthur, M., Leimkuhler, C., Tao, J., Kahne, D., and
Walsh, C.T. (2004). Characterization of a regiospecific epivan-
cosaminyl transferase GtfA and enzymatic reconstitution of the
antibiotic chloroeremomycin. Proc. Natl. Acad. Sci. USA 101,
4390–4395.
16. Trauger, J.W., Kohli, R.M., and Walsh, C.T. (2001). Cyclization of
backbone-substituted peptides catalyzed by the thioesterase
domain from the tyrocidine nonribosomal peptide synthetase.
Biochemistry 40, 7092–7098.
17. Kohli, R.M., Trauger, J.W., Schwarzer, D., Marahiel, M.A., and
Walsh, C.T. (2001). Generality of peptide cyclization catalyzed
by isolated thioesterase domains of nonribosomal peptide syn-
thetases. Biochemistry 40, 7099–7108.
18. Kohli, R.M., Takagi, J., and Walsh, C.T. (2002). The thioesterase
domain from a nonribosomal peptide synthetase as a cycliza-
tion catalyst for integrin binding peptides. Proc. Natl. Acad.
Sci. USA 99, 1247–1252.
19. Kohli, R.M., Burke, M.D., Tao, J., and Walsh, C.T. (2003). Che-
moenzymatic route to macrocyclid hybrid peptide/polyketide-
like molecules. J. Am. Chem. Soc. 125, 7160–7161.
20. Hancock, R.E.W., and Lehrer, R. (1998). Cationic peptides: a
new source of antibiotics. Trends Biotechnol. 16, 82–88.
21. Kondejewski, L.H., Farmer, S.W., Wishart, D.S., Kay, C.M., Han-
cock, R.E.W., and Hodges, R.S. (1996). Modulation of structure
and antibacterial and hemolytic activity by ring size in cyclic
gramicidin S analogs. J. Biol. Chem. 271, 25261–25268.
22. Kondejewski, L.H., Jelokhani-Niaraki, M., Farmer, S.W., Lix, B.,
Kay, C.M., Sykes, B.D., Hancock, R.E.W., and Hodges, R.S.
(1999). Dissociation of antimicrobial and hemolytic activities in
cyclic peptide diastereomers by systematic alterations in am-
phipathicity. J. Biol. Chem. 274, 13181–13192.
23. Mootz, H., and Marahiel, M. (1997). The tyrocidine biosynthesis
operon of Bacillus brevis: complete nucleotide sequence and
biochemical characterization of functional internal adenylation
domains. J. Bacteriol. 179, 6843–6850.
24. Walsh, C.T., Meyers, C.L.F., and Losey, H.C. (2003). Antibiotic
glycosyltransferases: antibiotic maturation and prospects for
reprogramming. J. Med. Chem. 46, 3425–3436.
25. Friedrich-Bochnitschek, S., Waldmann, H., and Kunz, H. (1989).
Allyl esters as carboxy protecting groups in the synthesis of
O-glycopeptides. J. Org. Chem. 54, 751–756.
26. Salvador, L.A., Elofsson, M., and Kihlberg, J. (1995). Prepara-
tion of building blocks for glycopeptide synthesis by glycosyla-
tion of Fmoc amino acids having unprotected carboxyl groups.
Tetrahedron 51, 5643–5656.
27. Fahmi, N.E., Golovine, S., Wang, B., and Hecht, S.M. (2001).
Studies toward the site specific incorporation of sugars into
proteins: synthesis of glycosylated aminoacyl-tRNAs. Carbo-
hydr. Res. 330, 149–164.
28. Saha, U.K., and Schmidt, R.R. (1997). Efficient synthesis of
O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-serine and -threo-
nine building blocks for glycopeptide formation. J. Chem. Soc.,
Perkin Trans. 1 1, 1855–1860.
